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Abstract
Background Gamma-hydroxybutyrate (GHB) dependence
is associated with a severe, potentially lethal, withdrawal
syndrome and relapse rates as high as 60% within 3 months
of detoxification. Baclofen has been shown to decrease
self-administration of GHB in mice and reduce relapse in a
case series of GHB-dependent patients. Controlled studies
on the effectiveness of baclofen to prevent relapse in GHB-
dependent patients are lacking.
Aim The aim of this study was to assess effectiveness of
baclofen in preventing relapse in GHB-dependent patients.
Methods This was an out-patient, multicentre, open-label,
non-randomized, controlled trial in GHB-dependent
patients (n = 107) in the Netherlands. Treatment as usual
(TAU, n = 70) was compared with TAU plus baclofen
45–60 mg/day for 3 months (n = 37). Outcome measures
were rates of lapse (any use) and relapse (using GHB on
average once a week or more), based on self-report. Side
effects were monitored with a baclofen side-effects ques-
tionnaire. Treatment groups were compared using Chi
square analyses, with both per-protocol (PP) and intention-
to-treat (ITT) analyses.
Results GHB-dependent patients treated with baclofen
after detoxification showed no reduced lapse rates, but
reduced relapse and dropout rates, compared with patients
receiving TAU only (24 vs 50%). While both ITT and PP
analyses revealed similar results, the effectiveness of
baclofen prescribed PP was slightly higher than in ITT
analysis. Patients reported overall limited side effects, with
the most frequently reported being feeling tired (28%),
sleepiness (14%) and feeling depressed (14%). No serious
adverse events were reported.
Conclusions This study showed potential effectiveness of
baclofen in preventing relapse in patients with GHB
dependence after detoxification. Though promising, future
studies with longer follow-up and a randomized double-
blind design should confirm these findings before recom-
mendations for clinical practice can be made.
Clinical trial registration Netherlands Trial Register with
number NTR4528.
Key Points
Baclofen up to 60 mg daily might be effective in
preventing relapse and increasing treatment
adherence in patients with GHB use disorder.
The use of baclofen up to 60 mg daily in patients
with GHB use disorder seems safe, when prescribed
according to the protocol.
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1 Introduction
In Europe, misuse of gamma-hydroxybutyrate (GHB) has
increased over the past decade, particularly in the Nether-
lands, Norway, Spain and the UK [1]. GHB originally
emerged in the 1990s as an innocent party drug, but later
proved to be highly addictive. Precise prevalence rates are
unknown due to a lack of systematic surveillance on GHB
use [2]. Physical dependence on GHB can develop within
weeks, when used daily [3]. GHB dependence is associated
with a severe, potentially lethal withdrawal syndrome and
high relapse rates of 60% within 3 months of detoxification
[4]. However, studies on relapse prevention in GHB
dependence are lacking.
GHB is a short-chain fatty acid, which is biosyntheti-
cally derived from the inhibitory neurotransmitter GABA
[5]. It occurs naturally in the brain, predominantly in the
hypothalamus and basal ganglia [6, 7]. GHB binds to
GABA-A receptors, GABA-B receptors and GHB recep-
tors [8]. It has a rapid onset of action after ingestion,
reaching maximum concentration (Cmax) in a short period
(Tmax = 20–60 min), and a short half-life (T-
= 30–60 min). The clinical effects of GHB include seda-
tion, euphoria and, in higher doses, hypoventilation and
coma; see [9] for further details.
Baclofen might be an adequate substitute for GHB. It is
a high-affinity GABA-B receptor agonist, similar to GHB
[10, 11], but with a longer half-life (T = 2–6 h). This has
the theoretical advantage of more stable drug-plasma
levels, and subsequent GABA-B activation, with less fre-
quent dosing (i.e. 3 times daily, instead of 12) [4]. Indeed,
one animal study in mice showed that baclofen reduced
GHB self-administration [12]. To date, only one case series
on baclofen treatment (30–60 mg/day) in GHB dependence
has been reported, showing 3-month abstinence in nine out
of eleven cases [13]. Baclofen has also been shown to
increase abstinence rates and reduce craving and anxiety in
alcohol-dependent patients [14–18]. However, several
studies failed to replicate these effects [19, 20].
These findings warrant further studies on the potential
efficacy of baclofen in the treatment of GHB use disorders.
To our knowledge, no clinical studies on the effects of
baclofen in GHB use disorders have been published. Here,
we investigated the effectiveness of baclofen in recently
detoxified GHB-dependent patients to prevent relapse in an
open-label, non-randomized, controlled clinical trial.
Specifically, we tested the hypothesis that patients receiv-
ing baclofen on top of treatment as usual (TAU) after GHB
detoxification have decreased relapse rates compared with
patients receiving TAU.
2 Methods
2.1 Study Design
The effectiveness of baclofen was assessed in a multicen-
tre, open-label, non-randomized, controlled clinical trial
(see protocol publication [21]). After detoxification from
GHB, patients received TAU or TAU combined with
baclofen, based on patient preference. Participants pro-
vided written informed consent. The study was approved
by the Medical Ethics Committee, Twente Medical School
(METC/14015.am) study number NL40321.044.13. The
study was registered in the Netherlands Trial Register with
number NTR4528.
2.2 Participants
GHB-dependent patients (according to DSM-IV criteria of
substance dependence) were recruited at six addiction care
facilities (IrisZorg, Mondriaan, Novadic-Kentron, Tactus,
Victas and VNN) in the Netherlands, when admitted for
detoxification. Inclusion criteria comprised completed
GHB detoxification, wish for abstinence, continuing out-
patient treatment after detoxification, age between 18 and
40 years, and comprehension of Dutch. Exclusion criteria
comprised physical contra-indications for baclofen (e.g.
liver problems, renal impairment, hypertension, diabetes
mellitus, seizure disorder and pregnancy), severe psychi-
atric conditions (e.g. bipolar disorder, major depression,
psychotic disorders and suicidal ideations), use of anxi-
olytics, stimulants or hypnotics after detoxification, or
previous misuse of baclofen. Of 137 GHB-dependent
patients admitted for detoxification, 107 were eligible for
participation. Thirty-seven patients received baclofen on
top of TAU; 70 received TAU only. During admission, a
physician informed patients about the baclofen study. A
flowchart is shown in Fig. 1.
Fig. 1 Flowchart of participants included in the study. ITT intention
to treat, PP per protocol, TAU treatment as usual
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2.3 Sample Size Calculation
Sample size calculation was based on the effectiveness of
baclofen in alcohol use disorders. Though the literature on
baclofen’s efficacy in alcohol use disorders is contradic-
tory, several studies do suggest a beneficial response of
baclofen versus placebo (abstinence rates 70% vs 20–30%)
[18, 22]. Anticipating a smaller effectiveness in GHB
dependence (3-month abstinence rates 60 vs 40%) based on
our previous studies [4], approximately 30 patients per
group are needed in order to detect any significant effects
of baclofen, with a = 0.05 and b = 0.80 [21].
2.4 Treatment Intervention
2.4.1 Baclofen
Participants initially received 15 mg per day, divided over
three doses, which was gradually increased over a period of
10 days to 45 mg daily. When patients reported no or
limited effects of baclofen on anxiety and craving after
2 weeks without side effects, the dose was increased to a
maximum of 60 mg daily. This dose was maintained for
10 weeks. In case of relapse or adverse events, immediate
cessation of treatment was considered to avoid intoxication
hazards. Compliance was assessed during weekly meetings
between the prescribing physician and the patient.
2.4.2 Treatment as Usual (TAU)
All participants received TAU as provided by their addic-
tion treatment centre, including cognitive behavioural
therapy with additional treatment for social, psychiatric
and medical problems if necessary.
2.5 Outcome Measures
2.5.1 Lapse and Relapse
Lapse and relapse were measured by self-report on a
questionnaire at 3 months’ follow-up. Lapse was defined as
any use of GHB and relapse as weekly use of GHB during
the past 3 months. Patients who were no longer in care at
follow-up were contacted via telephone and e-mail. Those
unavailable for follow-up were considered relapsed.
2.5.2 Side Effects
Safety of baclofen was monitored using a baclofen side
effects questionnaire, both self-monitored and observed by
treating physicians. This questionnaire was based on the
side effects of baclofen reported in the literature [13],
containing 21 items with a five-point Likert scale (range:
0 = never to 4 = always). Examples are vomiting, nausea
and diarrhoea. See Supplementary Table 1 in the electronic
supplementary material for the complete list.
2.6 Analysis
Demographics were calculated using descriptive statistics
and compared between groups using univariate analysis of
variance (ANOVA) and Chi square analyses. Lapse,
relapse and relapse including drop-out rates in each group
were compared using Chi square analyses. In contrast to
the original protocol publication [21], we only analysed
primary outcomes using both intention to treat (ITT) and
per protocol (PP) analyses due to the limited influx of
patients receiving baclofen after a prolonged inclusion
period (n = 37 instead of n = 80). In the more conservative
ITT analyses, all participants receiving baclofen were
compared with TAU. In the PP analyses, only those par-
ticipants receiving baclofen according to the protocol were
compared with TAU.
Though a historical control group was available for
comparison [13], only the current control group was
included in the analyses. First, the current control group is
substantially larger than the intervention group, making
addition of an extra control group redundant. Second,
relapse rates in the current control group were substantially
lower compared with our historical control group (50 vs
65%, respectively). Finally, the current control group was
more comparable to the baclofen group in terms of
received TAU. Therefore, adding a historical control group
to the analyses was considered of no added value.
All analyses were carried out in SPSS version 21, with
a\ 0.05 considered significant.
3 Results
3.1 Demographics
Patients in the baclofen group were more often male than in
the TAU group, but gender was not related to treatment
outcome. There were no other differences in demographics,
GHB use or psychiatric comorbidity, see Table 1. Of the
37 patients receiving baclofen (included in ITT analysis),
13 received baclofen according to protocol (included in PP
analysis).
3.2 Effectiveness
ITT analysis showed no difference in lapse rates
(v2 = 0.20, p = 0.885) and relapse rates excluding drop-out
(v2 = 3.29, p = 0.069) in the baclofen-treated group com-
pared with TAU, see Table 2. In the baclofen group,
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relapse rates including drop-out as relapse were lower
compared with TAU (v2 = 6.59, p = 0.010). PP analysis
showed no difference in lapse rates (v2 = 1.99. p = 0.158),
but lower relapse rates in the baclofen group when drop-out
rates were not included (v2 = 3.97, p = 0.046) and inclu-
ded as relapse (v2 = 5.31, p = 0.021) compared with TAU,
see Table 3.
3.3 Side Effects
Patients reported overall limited side effects, with the most
frequently reported being feeling tired (28%), sleepiness
(14%) and feeling depressed (14%). No serious adverse
events were reported.
4 Discussion
This is the first case–control study evaluating the effec-
tiveness of baclofen to prevent relapse in GHB-dependent
patients. Patients receiving baclofen per protocol after
detoxification showed reduced relapse rates compared with
patients receiving TAU, supported by a similar trend
towards beneficial effects of baclofen in the ITT analysis.
Mild tiredness, sleepiness and depressed feelings were
reported in the baclofen group as the most relevant side
effects of baclofen.
These results are comparable with an earlier case series
(n = 11) on baclofen treatment in GHB-dependent patients,
showing 81% abstinence rates during 3 months’ follow-up,
without significant side effects [13]. Similarly, Fattore et al.
[12] showed prevention of self-administration of GHB in
Table 1 Demographics and GHB use per sub group
Treatment as usual (N = 70) Baclofen ? treatment as usual (N = 37) Test statistic p value
Male (%) 54 74 v2 = 4.68 0.030
Age, mean (SD) 28.9 (7.8) 29.5 (7.0) F (1.98) = 0.014 0.905
Employment (%) 31 32 v2 = 0.01 0.916
GHB use, mean (SD)
Months using GHB 58.3 (42.2) 63.5 (43.0) F (1.85) = 0.285 0.595
Months using daily GHB 27.4 (28.2) 41.2 (43.0) F (1.79) = 2.958 0.089
GHB gram daily 55.6 (53.8) 46.1 (40.9) F (1.93) = 0.797 0.374
Interval between doses (h) 1.8 (0.73) 1.84 (0.64) F (1.85) = 0.114 0.736
GHB Gamma-hydroxybutyrate
Table 2 Comparison of
(re)lapse in GHB use in the
3 months after detoxification
between patients prescribed
baclofen (ITT) and patients who
received treatment as usual
TAU Baclofen ? TAU Test statistic p value
Patient completed follow-up 55 35
Lapse (any use) 47% (n = 26) 46% (n = 16) v2 = 0.20 0.885
Relapse (weekly use) 38% (n = 21) 20% (n = 7) v2 = 3.29 0.069
Patients including drop-out 70 37
Relapsea 50% (n = 35) 24% (n = 9) v2 = 6.59 0.010
GHB Gamma-hydroxybutyrate, ITT intention to treat, TAU treatment as usual
aDrop-out is considered relapse in GHB-dependent patients, therefore only relapse is mentioned
Table 3 Comparison of
(re)lapse in GHB use in the
3 months after detoxification
between patients prescribed
baclofen according to the study
protocol (PP) and patients who
receive treatment as usual
TAU Baclofen ? TAU Test statistic p value
Patient completed follow-up 55 12
Lapse (any use) 47% (n = 26) 25% (n = 3) v2 = 1.99 0.158
Relapse 38% (n = 21) 8% (n = 1) v2 = 3.97 0.046
Patients including drop-out 70 13
Relapsea 50% (n = 35) 15% (n = 2) v2 = 5.31 0.021
GHB Gamma-hydroxybutyrate, PP per protocol, TAU treatment as usual
aDrop-out is considered relapse in GHB dependent patients, therefore only relapse is mentioned
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mice when treated with baclofen (0.625 and 1.25 mg/kg).
Importantly, a lower dosage of baclofen (0.312 mg/kg) did
not prevent GHB self-administration. There is currently no
consensus on the most appropriate dose of baclofen in
addiction treatment. In line with the previous case series,
we prescribed a relatively low dosage of baclofen
(45–60 mg daily) in comparison with studies on alcohol
dependence (up to 300 mg daily [23]). As higher doses of
baclofen might be more effective, future studies on
baclofen effectiveness in GHB dependence should also
study higher doses of baclofen. However, caution is war-
ranted as data about safety of high-dose baclofen are
limited.
GHB, baclofen and alcohol share a similar pharmaco-
logical profile. Studies on alcohol dependence have shown
that GHB is effective in reducing alcohol craving and
intake [24]. Therefore, it is conceivable that baclofen
should be effective in reducing GHB dependence in view
of its efficacy in reducing alcohol dependence [25]. In light
of the longer half-life of baclofen compared with GHB, it
can also be speculated that baclofen might be considered a
substitute for GHB [26]. The currently poor prognosis in
GHB dependence and severity of complications might
justify a substitution therapy approach [4]. Recently,
baclofen gained attention for its potential effectiveness in
the detoxification of GHB [27]. One could also suggest
using baclofen to ameliorate GHB withdrawal during
detoxification, without tapering off completely, in order to
prevent relapse. This would likely increase treatment
adherence in some patients, preventing them from dropping
out of treatment and relapse in GHB use.
Given the explorative, non-randomized, open-label
design of our study, the results need to be interpreted with
caution and further studies are needed in order to confirm
our findings. Several limitations should be considered
when interpreting the results. First, sample size was limited
and lower than anticipated. Moreover, patients who chose
baclofen treatment might have been more motivated to
achieve full abstinence, adding to the chance of good
outcome at follow-up. However, we did observe similar
findings to previous animal work and a case series of GHB-
dependent patients [12, 13]. The observed effectiveness of
baclofen, despite a limited sample size, does suggest
treatment potential of baclofen in patients with GHB use
disorders. Second, TAU was not specified in the current
study. Any variation in TAU between groups might con-
found the results. While we have no such indication when
it comes to psychosocial treatment, it is, however, possible
that some patients in the TAU group were prescribed
benzodiazepines on top of their psychosocial treatment.
Therefore, a potential confounding effect cannot be fully
ruled out. Third, abstinence was not confirmed using sys-
tematic urine or blood tests, due to the narrow timeframe in
which GHB can be detected as a result of its short half-life
[28]. We relied on self-report measures, with potential
recall bias, particularly given the open-label design of the
study. Compliance with the baclofen treatment was also
assessed by self-report, during weekly meetings between
the prescribing physician and the patient. Pill count was not
used. This is a potential confounder of the data, since
compliance is considered highly relevant for the effec-
tiveness of baclofen. Finally, follow-up duration was
3 months after detoxification, which makes drawing con-
clusions about long-term effects impossible. Fourth, side
effects were not measured in the TAU group, therefore
reported side effects cannot be solely attributed to baclo-
fen. Many of the reported side effects are common in GHB-
dependent patients in general after detoxification [4].
Future studies should address long-term efficacy of
baclofen in GHB dependence, using placebo-controlled,
randomized designs in substantially large samples.
5 Conclusion
This study showed that baclofen could be a potential can-
didate for preventing relapse in GHB-dependent patients
after detoxification, particularly when administered strictly
according to the protocol. Though promising, future studies
with longer follow-up and a randomized double-blind
design should be conducted to confirm these findings,
before recommendations for clinical practice can be made.
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